Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: Menstruation and pregnancy outcomes

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 133-138

  Wong, M ^a,b   O'Neill, S ^a,c   Walsh, G ^a   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Early breast cancer; Goserelin; Ovarian protection

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GOSERELIN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY FUNCTION; PREGNANCY OUTCOME; PREMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84871598343     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds250     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials. Lancet 2012; 379: 432-444.
2. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 26: 1045-1051.
3. Partridge AH, Gelber S, Peppercorn J et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
4. Ataya K, Rao LV, Lawrence E et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52: 365-372.
5. Blumenfeld Z, Avivi I, Linn S et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by gonodotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996; 11: 1620-1626.
6. Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus by chemotherapy. Lupus 2000; 9: 401-405.
7. Fox K, Ball J, Mick R et al. Preventing chemotherapy-associated amenorrhea (CRA) with leuprolide in young women with early-stage breast cancer. Am Soc Clin Oncol 2001; 20: 25a abstract no. 98.
8. Pereya Pacheco B, Mendez Ribas JM, Milone G et al. Use of GnRH analogues for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001; 81: 391-397.
9. Recchia F, Saggio G et al. Gonadotrophin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006; 106: 514-523.
10. Del Mastro L, Boni L, Michelotti A et al. Effect of the gonodotrophin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in pre-menopausal women with breast cancer. JAMA 2011; 306: 269-276.
11. Gerber B, von Minckwitz G, Stehle H et al. Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy. The GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341.
12. Urruticoechea A, Arnedos M, Walsh G et al. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Res Treat 2008; 110: 411-416.
13. Swain SM, Jeong JH, Geyer CE et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-2065.
14. Swain SM, Jeong JH, Wolmark N. Amenorrhea from breast cancer therapy-not a matter of dose. N Engl J Med 2010; 363: 2268-2270.
15. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004; 10: 251-266.
16. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embryo, oocytes or ovaries. Oncologist 2007; 12: 1044-1054.
17. Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981; 1: 1132-1134.
18. Badawy A, Elnasher A, El-Ashry M et al. Gonodotrophin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697.
19. Fox K, Scialla J et al. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer. Am Soc Clin Oncol 2003; 22: 13.
20. Recchia F, Sica G, De Filippis S et al. Goserelin as ovarian protection in the adjuvant treatment of pre-menopausal breast cancer: a phase II pilot study. Anticancer Drugs 2002; 13: 417-424.
21. Leonard RC, Adamson D, Anderson R et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010; 28(suppl): 15S.
22. Ismail-Khan R, Minton S, Cox C et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. J Clin Oncol 2008; (suppl): 26.
23. Munster PN, Moore AP, Ismail-Khan R et al. Randomized trial using gonadotrophin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538.
24. Kim SS, Lee JR, Jee BR et al. Use of hormonal protection for chemotherapyinduced gonodatoxicity. Clin Obstet Gynecol 2010; 53: 740-752.
25. Lucerna E, Bernal DP, Lucerna C et al. Successful ongoing pregnancies after vitrification of oocytes. Fert Steril 2006; 85: 108-111.
26. Dolmans MM, Donnez J, Camboni A et al. IVF outcome in patients with orthotopically transplanted ovarian tissue. Hum Reprod 2009; 24: 2778-2787.
27. Oktay K. Evidence for limiting ovarian tissue harvesting for the purpose of transplantation to women younger than 40 years of age. J. Clin Endocrinol Metab 2002; 87: 1907-1908.
28. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 2012; 26: 379-390.
29. International Breast cancer Study Group. Late effects of adjuvant oophorectomy and chemotherapy upon pre-menopausal breast cancer patients. Ann Oncol 1990; 1: 30-35.
30. Rivkin SE, Green S, O'Sullivan J et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for pre-menopausal, node-positive, and estrogen receptorpositive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol 1996; 14: 46-51.
31. Arriagada R, Le MG, Spielmann M et al. Randomized trial of adjuvant ovarian suppression in 926 pre-menopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 2005; 16: 389-396.
32. Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in pre-menopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007; 99: 516-525.
33. Del Mastro L, Venturini M, Sertoli MR et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43: 183-190.